Article

Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.

Baylor College of Medicine, Menninger Department of Psychiatry & Behavioral Sciences, 2002 Holcombe Boulevard, Houston, TX 77030, USA.
Drug and alcohol dependence (Impact Factor: 3.6). 09/2009; 106(2-3):173-80. DOI: 10.1016/j.drugalcdep.2009.08.013
Source: PubMed

ABSTRACT Methamphetamine is a highly addictive stimulant and long-term exposure leads to reductions in dopamine. One therapeutic strategy is to develop and test compounds that normalize dopamine. The primary aim of this study was to determine the safety of modafinil treatment during methamphetamine exposure in a controlled clinical setting. Methamphetamine-dependent volunteers (N=13), who were not seeking treatment, were randomized to receive either modafinil (200mg, PO) or matching placebo over three days (Days 1-3 or Days 8-10). On Day 1, subjects were randomized to modafinil or placebo in the morning, and then 3 and 6h later received infusions of methamphetamine (0 and 30 mg, i.v.), after which cardiovascular and subjective effects were assessed. On Day 3, participants completed i.v. self-administration sessions during which they made 10 choices for low doses of methamphetamine (3mg, i.v.) or saline. Days 4-7 were used as a washout period. On Day 8 participants were assigned to the alternate study medication (placebo or modafinil), and the same testing procedures were repeated through Day 10. The data reveal that modafinil treatment was well-tolerated and not associated with increased incidence of adverse events. In general, modafinil reduced by approximately 25% ratings of methamphetamine-induced "Any Drug Effect", "High", and "Want Methamphetamine", and reduced total number of choices for methamphetamine and monetary value of methamphetamine, though none of these measures reached statistical significance. Given these encouraging, though non-significant trends, the primary conclusion is that it appears safe to proceed with modafinil in further clinical evaluations of therapeutic efficacy.

0 Bookmarks
 · 
71 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methamphetamine use is increasing in the US. Although there are no Food and Drug Administration (FDA)-approved medications for methamphetamine dependence, preclinical and clinical studies suggest that methamphetamine users may benefit from treatments that enhance cholinergic neurotransmission. Consequently, we determined the safety and the efficacy of varenicline treatment, a partial agonist at α4β2 and a full agonist at α7 nicotinic acetylcholine receptors, to reduce positive subjective effects produced by smoked methamphetamine. Additionally, the effects of treatment with varenicline on the cardiovascular and reinforcing effects of methamphetamine were determined. We conducted a double-blind, placebo-controlled, within-subjects trial of varenicline vs. placebo in methamphetamine-dependent volunteers who were not seeking treatment. Participants were randomly assigned to receive one dose of varenicline (0, 1, or 2 mg) po BID, titrated up to the target dose over days 1-7, during each of three separate inpatient phases. Safety measures included the frequency, duration, severity, and relatedness of adverse events reported. Positive subjective effects included 'Any drug effect', 'High', 'Good effects', 'Stimulated', and 'Drug liking', which were rated by participants before and for 1 h after smoking methamphetamine (0, 10, and 30 mg). There were no serious adverse events and no differences in adverse events reported during the three phases. Varenicline (2 mg) significantly reduced ratings of 'Any drug effect' and 'Stimulated', as well as attenuated ratings of 'High', 'Drug liking', and 'Good effects', produced by methamphetamine (30 mg). The ability of varenicline to attenuate the positive subjective effects of methamphetamine in the laboratory suggests that varenicline should continue to be explored as a treatment for methamphetamine dependence.
    The International Journal of Neuropsychopharmacology 02/2014; 17(2):223-33. DOI:10.1017/S146114571300134X · 5.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: Methamphetamine (MA) use disorders are major public health problems nationally and worldwide and treatment remains an unmet need. Objectives: (1) To review preclinical and clinical studies identifying the dopamine D3 receptor as a therapeutic target for substance use disorders (SUDs), including MA dependence, (2) to consider buspirone (Buspar®) as a potential medication based on its dopamine D3 receptor antagonist properties, and (3) to evaluate the safety and initial efficacy of buspirone in a pilot study of MA-dependent individuals. Methods: Literature on the dopamine D3 receptor as a therapeutic target and on the potential of buspirone as a novel therapy for MA dependence was reviewed. The cardiovascular and subjective effects of intravenous MA challenge were assessed in five non-treatment seeking individuals. Participants met DSM-IV criteria for MA dependence and were treated subacutely (9 days) with buspirone (60 mg daily). Results: The literature identified the dopamine D3 receptor as a therapeutic target for MA dependence, a safe and approved medication, and a valuable opportunity to re-purpose buspirone for treating MA dependence and perhaps other SUDs. Pilot data (n = 5) indicated that buspirone is safe in MA-using individuals and comparison against historical placebo data from this laboratory suggested that at least some aspects of the subjective properties of MA may be diminished during buspirone treatment. Conclusion: Future studies should include a small-scale, placebo-controlled Phase IIa trial of buspirone in MA dependence.
    The American Journal of Drug and Alcohol Abuse 01/2014; 40(1):1-9. DOI:10.3109/00952990.2013.858723 · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Concurrent administration of dopamine and serotonin reuptake inhibitors reduces cocaine self-administration in monkeys. Consonant with this, clinical trials assessing modafinil and selective serotonin reuptake inhibitors alone show some efficacy as potential pharmacotherapies for cocaine dependence. We hypothesized that combining modafinil with escitalopram would attenuate the euphoric effects of cocaine to a greater degree than modafinil alone. Methods Ina randomized, double blind, parallel groups design participants received either placebo (0 mg/day; n = 16), modafinil (200 mg/day; n = 16), escitalopram (20 mg/day; n = 17), or modafinil + escitalopram (200 + 20 mg/day; n = 15) for 5 days. On day 5, during separate sessionsparticipants received an intravenous sample of cocaine (0 or 20 mg; randomized) and five $1 bills. Participants rated the subjective effects of the infusionsand subsequently made choices to either return $1 and receive another infusion or keep $1 and receive no infusion. Results Compared to saline, cocaine (20 mg) significantly (p ≤ 0.008)increased most ratings, including“Good Effects”, “Stimulated”, and “High”.Relative to placebo, modafinil significantly (p≤ 0.007) attenuated subject-rated increases of “Any Drug Effect”, “High”, “Good Effects”, and “Stimulated” produced by cocaine. Compared to saline, participants chose cocaine infusions significantly more; however, no treatment significantly reducedchoices for cocaine infusions. Escitalopram did not enhance the efficacy of modafinil to reduce any measure. Conclusions Modafinil attenuated many positive subjective effects produced by cocaine; however, escitalopram combined with modafinildid not enhance the efficacy of modafinil to reduce cocaine effects.
    Drug and Alcohol Dependence 08/2014; 141. DOI:10.1016/j.drugalcdep.2014.05.008 · 3.28 Impact Factor

Full-text (2 Sources)

Download
14 Downloads
Available from
May 30, 2014